Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M500786200 on February 24, 2005

J. Biol. Chem., Vol. 280, Issue 18, 17880-17890, May 6, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/18/17880    most recent
M500786200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feige, J. N.
Right arrow Articles by Desvergne, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feige, J. N.
Right arrow Articles by Desvergne, B.
Related Collections
Right arrow Papers Of The Week
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Fluorescence Imaging Reveals the Nuclear Behavior of Peroxisome Proliferator-activated Receptor/Retinoid X Receptor Heterodimers in the Absence and Presence of Ligand*{diamondsuit}

Jérôme N. Feige{ddagger}§, Laurent Gelman{ddagger}§, Cicerone Tudor¶, Yves Engelborghs¶, Walter Wahli{ddagger}, and Béatrice Desvergne{ddagger}||

From the {ddagger}Center for Integrative Genomics, NCCR Frontiers in Genetics, University of Lausanne, CH-1015 Lausanne, Switzerland and the Laboratory of Biomolecular Dynamics, Katholieke Universiteit Leuven, B3001 Leuven, Belgium

Received for publication, January 21, 2005 , and in revised form, February 23, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
In a global approach combining fluorescence recovery after photobleaching (FRAP), fluorescence correlation spectroscopy (FCS), and fluorescence resonance energy transfer (FRET), we address the behavior in living cells of the peroxisome proliferator-activated receptors (PPARs), a family of nuclear receptors involved in lipid and glucose metabolism, inflammation control, and wound healing. We first demonstrate that unlike several other nuclear receptors, PPARs do not form speckles upon ligand activation. The subnuclear structures that may be observed under some experimental conditions result from overexpression of the protein and our immunolabeling experiments suggest that these structures are subjected to degradation by the proteasome. Interestingly and in contrast to a general assumption, PPARs readily heterodimerize with retinoid X receptor (RXR) in the absence of ligand in living cells. PPAR diffusion coefficients indicate that all the receptors are engaged in complexes of very high molecular masses and/or interact with relatively immobile nuclear components. PPARs are not immobilized by ligand binding. However, they exhibit a ligand-induced reduction of mobility, probably due to enhanced interactions with cofactors and/or chromatin. Our study draws attention to the limitations and pitfalls of fluorescent chimera imaging and demonstrates the usefulness of the combination of FCS, FRAP, and FRET to assess the behavior of nuclear receptors and their mode of action in living cells.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The nucleus comprises different subdomains whose biological functions remain often very elusive, if known at all, and that differ fundamentally from cytoplasmic compartments in that they are not delineated by membranes (1, 2). Several proteins or complexes involved in processes as diverse as chromatin remodeling, transcription, and RNA processing form nuclear speckles throughout the nucleoplasm. These compartments would actually result from the temporary association of highly mobile components, which shuttle between these sites (3).

Nuclear receptors are one of the most abundant classes of transcriptional regulators in metazoans. They compose a large family of ligand-activated proteins among which are the steroid hormone receptors, the thyroid hormone receptors (TRs),1 the vitamin D receptor (VDR), the retinoic acid receptors (RARs), as well as the peroxisome proliferator-activated receptors (PPARs). It is generally assumed that, upon ligand binding, nuclear receptors either homodimerize or heterodimerize with the retinoid X receptor (RXR) and bind to specific responsive elements in the enhancer regions of their target genes. This promotes gene activation, after a complex array of events including both dissociation from and association with numerous cofactors (4). The three PPAR isotypes (named {alpha}, {beta}/{delta}, and {gamma} or NR1C1, NR1C2, and NR1C3 (5)) are mainly involved in lipid and glucose homeostasis, regulation of food intake and body weight, and control of inflammation and wound healing (6, 7). They are activated by naturally occurring or metabolized fatty acids derived from the diet or from intracellular signaling pathways and induce gene transcription as heterodimers with RXRs (8). PPARs are also very important therapeutic targets for the treatment of hyperlipidemia and type 2 diabetes.

Recent developments in live cell imaging have prompted investigations on the localization and mobility of nuclear receptors to decipher the molecular mechanisms underlying transcriptional activation. Genetically encoded fluorescent proteins (FPs) allow to monitor directly in living cells the behavior of proteins in their physiological context (9). For instance, it is possible to assess the dynamics of a protein by fluorescence recovery after photobleaching (FRAP) and fluorescence correlation spectroscopy (FCS) and to evaluate the interaction between two proteins by fluorescence resonance energy transfer (FRET).

Classical confocal microscopy combined with the use of FPs has first allowed to address a particularly interesting issue: the modulation of nuclear receptor localization upon ligand binding. Ligand treatment induces a redistribution of the glucocorticoid receptor (GR) (10), the androgen receptor (AR) (11, 12), the progesterone receptor (PR) (13), the mineralocorticoid receptor (MR) (14), and VDR (15) from the cytoplasm to the nucleus of various cell types. In contrast, other nuclear receptors such as the estrogen receptor (ER) (16–18), TR (19–21), RAR (19), and RXR (22) are confined in the nucleus both in the presence and absence of ligand. Ligand binding promotes the formation of nuclear speckled patterns for ER, GR, AR, TR, RAR, and RXR (see Ref. 23 for a review). These induced clusters only partially overlap with sites of transcription (24), and their role in nuclear receptor function awaits further elucidation. The need for quantification for these events then lead to the use of more elaborated techniques, such as FRAP. Mobility studies have focused on the diffusion of receptors through the nucleoplasm on the one hand and at specific interaction sites on chromatin on the other (25, 26). FRAP revealed that nuclear receptors move rapidly and that, at least for ER and GR, their motion in the nucleoplasm can be modulated by ligand binding (18, 19, 27, 28). Interestingly, other receptors such as TR and RAR do not exhibit the decreased mobility observed for ER and GR in the presence of ligand (19). Although recent reports have highlighted the influence of some molecular chaperones and of the proteasome on nuclear receptor mobility (18, 28–30), it is not clear at present which factors modulate and orientate nuclear receptor trafficking in the cell. The steps required to initiate transcription upon ligand binding (i.e. interaction with cofactors that allow chromatin remodeling and recruitment of the basic transcription machinery) also possibly influence nuclear receptor mobility. With that respect, FRET has emerged as a technique to characterize the mechanisms of cofactor recruitment following ligand binding in living cells (31, 32).

The microscopy studies published so far point to two major issues: first, despite some common features, each nuclear receptor displays specific distributions and dynamics, justifying a detailed analysis of each member of this family. Second, each technique has its own spatial and temporal resolutions, which sometimes limit a comprehensive study. Our aim here was to study PPAR action in living cells by combining complementary microscopy techniques. As a first step, we characterize the function of enhanced yellow fluorescent protein (EYFP)-PPAR fluorescent chimeras. The presence and the physiological relevance of the fluorescent spots that may arise under certain experimental conditions was analyzed, and we demonstrate that these structures are non physiological and result from overexpression in individual cells. Regarding mobility, FRAP indicates that PPARs are highly mobile receptors that are not immobilized by ligand binding. A FCS study undertaken to circumvent FRAP time scale limitations gives two new major insights into PPAR behavior in living cells. First, in the absence of ligand, PPARs diffuse in the nucleus either in association with very big complexes and/or transiently interact with relatively immobile nuclear components. Second, ligand binding slows down PPARs, most probably by enhancing interactions with cofactors and chromatin. Moreover, FRET experiments demonstrate that PPARs readily form heterodimers with RXR in the absence of ligand. Finally, this study suggests guidelines for an appropriate examination of molecular behaviors in living cells.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Materials—Rosiglitazone and 17{beta}-estradiol were purchased from Sigma, Wy14,643 from Cayman Chemical Co. (Ann Arbor, MI), and 9-cis-retinoic acid from Biomol Laboratories (Plymouth Meeting, PA). L-165041 was synthesized in the laboratory by Marco Alves. The antibody directed against PPAR{alpha} has been previously described (33), and those directed against PPAR{beta}, PPAR{gamma}, and GFP were purchased from Affinity Bioreagents (Golden, CO), Wak-Chemie (Steinbach, Germany), and Roche Diagnostics (Rotkreuz, Switzerland), respectively. The antibodies against the {alpha}/{beta} subunits of the 20 S proteasome and ubiquitylated proteins were from Affiniti Research Products (Mamhead, UK).

Plasmid Constructs—cDNAs encoding mouse PPAR{alpha}, PPAR{beta}, and PPAR{gamma}1 as well as RXR{alpha} were subcloned after PCR amplification into the pEYFP-N1 and -C1, and pECFP-N1 and -C1 plasmids (Clontech) using XhoI/BamHI, BglII/SalI, XhoI/KpnI, and BglII/SalI restriction sites, respectively. Wild-type mPPAR{alpha} was expressed from a cDNA cloned in the pBK-CMV vector. The pEYFPC1-ER{alpha} vector, the (PPRE)3-luciferase (Luc) reporter construct and the ECFP-DEVD-EYFP construct were kind gifts of Drs. H. Vogel (EPFL, Lausanne, Switzerland), R. M. Evans (Salk institute, San Diego, CA), and J. M. Tavaré (West-phalian Wilhelms University, Münster, Germany), respectively.

Cell Culture and Transient Transfection Assays—COS-7 and MCF-7 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Invitrogen). Penicillin and streptomycin (Invitrogen) were added to the medium at 100 units/ml and 100 µg/ml, respectively.

Transient transfection assays were performed using Lipofectamine 2000 (Invitrogen), and luciferase activity assays were performed with the Promega dual reporter kit, according to the manufacturers' instructions. Renilla luciferase encoded by the normalization vector phRLTK (Promega) was used as an internal control for firefly luciferase normalization. Cells were plated in 12-well plates for luciferase assays or 4-well LabTek chambered coverglasses (Nunc) for microscopy studies. Unless otherwise stated, transfections were performed with 100 ng of vector per cm2 cell culture plate. After transfection, cells were left to recover in medium supplemented with 10% fetal calf serum for 5 h and grown in serum-free medium in the presence of PPAR ligands or vehicles for 18 h. Ligand concentrations were: 10–5 M for Wy14,643, 5.10–6M for L-165041, 10–6 M for rosiglitazone, 10–6M for 9-cis-retinoic acid, and 10–8 M for 17{beta}-estradiol.

Western Blots—Cells or tissues were lysed in ice-cold lysis buffer (20 mM Tris, 400 mM KCl, 2 mM dithiothreitol, 0.1 mM EDTA, glycerol 20%) supplemented with complete protease inhibitors (Roche Diagnostics) with a Dounce homogenizer. Protein extracts were resolved by SDS-PAGE as previously described (34). Primary antibodies against PPAR{alpha}, PPAR{beta}, and PPAR{gamma} were all used at dilutions of 1:2000 and the anti-GFP antibody was diluted 1:5000. Detection was performed using chemiluminescence (ECL advance, Amersham Biosciences).

Pull-down Experiments—For DNA pull-downs, plates were coated with oligonucleotides containing the malic enzyme PPAR response element as previously described (35). For cofactor pull-downs, the GST-p3002–516 fusion protein was purified as described previously (34). For both DNA and cofactor pull-downs, whole-cell extracts from transfected COS-7 cells were incubated 2.5 h at 4 °C in pull-down buffer in the oligonucleotide coated plates or with the GST-p3002–516 coated beads, and the appropriate PPAR ligands (Wy14,643 at 100 µM, L-165041 at 50 µM, and rosiglitazone at 10 µM). Plates or beads were washed four times with binding buffer and samples were boiled with 40 µl of 2x SDS-PAGE buffer and analyzed by Western blot.

Immunofluorescence—Wounded skin was prepared as described previously (36). Skin cryosections or transfected cells were fixed in 4% paraformaldehyde for 10 min. For the anti-PPAR{beta} immunofluorescence, after an antigen-unmasking step (citrate buffer, pH 6, 100 °C, 10 min), the following processing was applied: wash with PBS, 0.1% Triton X-100 for 10 min; PBS for 5 min; 10% normal goat serum (Vector Laboratory) for 1 h; PBS, 2% BSA for 5 min. The primary antibody against PPAR{beta} (Affinity Bioreagents) was applied overnight at 4 °C at 1/100th in PBS, 2% BSA, and slices were then incubated with a fluorescein isothiocyanate-coupled goat anti-rabbit IgG secondary antibody. Antibody incubations were followed by two 5-min washes in PBS, 2% BSA, and samples were mounted in DAPI containing-Vectashield mounting medium (Vector Laboratories). For the anti-20 S proteasome and anti-ubiquitin immunofluorescence, a classical protocol was applied using PBS, 2% BSA as a blocking agent and antibody dilutions of 1/1000 for 1 h and 1/500 overnight at 4 °C, respectively. Labeling was then performed with a chicken anti-mouse secondary antibody coupled to Alexa594 (Molecular Probes).

Confocal Imaging—Live cells on LabTek chambered coverglasses were washed once with phenol red free Optimem medium (Invitrogen) containing ligands or their vehicles and observed in the same medium. For perfusion experiments, cells were grown on 18-mm round coverglasses, placed in a Ludin perfusion chamber (Life Imaging Service), and perfused at 200 µl/min. All observations were performed at 37 °C on a TCS SP2 AOBS confocal microscope (Leica) equipped with a whole-microscope incubator (Life Imaging Service). Acquisitions were performed with a 63x/NA 1.2 water immersion objective for live-cell imaging and a 63x/NA 1.4 oil immersion objective for immunofluorescence observation. Observation of EYFP fusion proteins was done by exciting at 514 nm and detecting emission between 525 and 575 nm. DAPI, fluorescein isothiocyanate, and Alexa594 were measured in the following respective settings: excitation 405 nm/emission 410–465 nm, excitation 488 nm/emission 500–600 nm, and excitation 594 nm/emission 620–660 nm. For quantitative analyses, background-corrected 8-bit images were acquired with identical settings (same laser power and detector gain) and quantified using the Leica Confocal Software version 2.4.

FRET Experiments—Transfections were performed as described above, but expression levels of donor and acceptor proteins were adjusted to similar levels by Western blot. Fluorescence was recorded in three different settings: CFPex, 405 nm/CFPem, 465–485 nm; YFPex, 514 nm/YFPem, 525–545 nm; FRETex, 405 nm/FRETem, 525–545 nm. Laser power and detector gain were adjusted in the different channels to observe equimolar concentrations of CFP and YFP at equal intensities (equimolar concentrations of CFP and YFP were obtained by expressing a fusion protein of CFP and YFP spaced by 475 residues). Settings were kept unchanged for analysis of all samples. CFP and YFP spectral bleed-throughs (BT) in the FRET setting were determined on cells expressing CFP or YFP alone by calculating the intensity (I) ratios in the appropriate settings (IFRET/ICFP and IFRET/IYFP, respectively). FRET measured in co-expressing cells was then corrected for spectral bleed-throughs and normalized (NFRET) for expression levels according to the following formula (37).

(Eq. 1)
The image of FRET was generated with the "PixFRET" plug-in for the ImageJ software. This plug-in can be downloaded from www.unil.ch/cig/page16989.html.

FRAP Experiments—FRAP experiments were performed on Leica TCS SP2 AOBS or Zeiss LSM510 confocal microscopes. The LSM510 microscope was equipped with an argon 488-nm laser and a 505–550-nm bandpass filter, and image analysis was performed with the Zeiss LSM software version 3.2. For qualitative analysis (images only), images were acquired with a 256 x 256-pixel resolution. However, for the quantitative analysis presented in Fig. 5 (recovery curves), the resolution was switched to 128 x 128 pixels, and forward-reverse scanning was applied allowing acquisition of images every 100 ms. Photobleaching was performed with maximal laser power of the 488 laser line, and bleaching time was minimized by analyzing bleaching efficiency on fixed cells (eight scans at 800 Hz on the TCS SP2 and 50 iterations on the LSM510). In Fig. 6 (LSM510), the bleached region was a thin strip (100 x 5 pixels) across the nucleus not exceeding 10% of the total nucleus area. Experiments were performed with a pinhole set to 2.5 airy units. Fluorescence intensities were calculated in the bleached zone and over the entire cell nucleus with NIH ImageJ version 1.30 or Zeiss LSM softwares. Fluorescence recovery was normalized to the bleaching of the entire nucleus as described previously (38): recovery = (It/Io)*(To/Tt), where It is the average intensity in the region of interest in time point t, Io the average intensity in the region of interest during prebleach, Tt is the total nuclear intensity at time point t, and To is the average total nuclear intensity during prebleach. To extract half-recovery times and percentages of immobilization, the Origin 7.5 software (OriginLab, Northampton, MA) was used for nonlinear regression analysis. Recovery curves were fitted to the following equation.

(Eq. 2)
Maximal recovery (Mr) was the sum of y0, A1, and A2, and half-recovery time the value of t when y = Mr/2.

FCS Experiments—FCS measurements were performed on a commercial LSM510 ConfoCor2 combination system (Zeiss, Jena, Germany) at room temperature. The 488-nm line of an argon-ion laser was focused through a Zeiss C-Apochromat 40x, NA 1.2 water immersion objective, and the fluorescence emission was recorded between 505 and 550 nm. The pinhole diameter was set to 90 µm, and detection was achieved using an avalanche photodiode. The 1/e2 lateral radii of the detection volume was determined to be ~0.18 µm (488 nm excitation) from calibration measurements using standard dye (Rhodamine 6G, Molecular Probes). This value was used to convert diffusion times into diffusion coefficients. The setup was shown to be able to produce correct diffusion coefficients (39). Fluorescence intensity fluctuations were recorded at five spots in each nucleus. At each spot, measurements were performed over 25 s and repeated five times. On average, nine cells were analyzed. The autocorrelation curves were fitted to a one component model of free diffusion in three dimensions to derive the translational diffusion time through the confocal volume. Data were evaluated by Levenberg-Marquardt nonlinear least squares fitting to the appropriate model equations, using the ConfoCor2 or Origin software. The sizes of the EYFP-PPAR complexes were estimated by multiplying the molecular mass of EYFP by the factor (DEYFP/DEYFP-PPAR)3, assuming spherical symmetry of the complexes and normal diffusion in the viscous medium of the nucleus (i.e. EYFP experiences the same viscosity as the EYFP-PPAR complexes (40)).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Characterization of EYFP-PPAR Chimeras—To monitor PPAR action in living cells, we constructed expression vectors for the different PPAR isotypes fused to EYFP either at their N or C terminus (EYFP-PPAR and PPAR-EYFP, respectively). Proper expression of the EYFP-PPAR{alpha}, -{beta}, and -{gamma}1 fusion proteins in COS-7 cells was confirmed by Western blot (Fig. 1A). Expression levels were not affected by the position of the fluorescent tag (data not shown).

The main properties of nuclear receptors, i.e. ligand, DNA, and cofactor binding, were assessed for each of the fusion proteins. DNA binding was tested by analyzing by Western blot the retention of wild-type PPAR{alpha}, EYFP-PPAR{alpha}, and PPAR{alpha}-EYFP from COS-7 cell extracts on a matrix coated with PPRE-containing oligonucleotides. In a similar assay, cofactor binding was assessed on a matrix coated with GST-p300. In these in vitro assays, PPAR{alpha} (Fig. 1B), PPAR{beta}, and PPAR{gamma} (data not shown) chimeras bound DNA and recruited p300 as well as their wild-type counterparts, and the EYFP fusion proteins displayed similar ligand-dependent binding to p300. We next assessed in COS-7 cells the transcriptional activity of these EYFP chimeras and of their wild-type counterparts on a reporter construct containing three copies of a PPRE. Importantly, because the vectors used to express the fusion proteins (pEYFP-N/C1) confer high expression levels, the amounts of vector transfected were adjusted to have similar expression of the wild-type and EYFP fusion proteins. The PPAR{alpha} fusion proteins could induce the transcription of the luciferase reporter gene by ~3-fold in the presence of a 10 µM concentration of the PPAR{alpha} agonist Wy14,643 (Fig. 1C), whereas under conditions giving similar expression levels, the wild-type protein could activate transcription of the reporter gene ~5-fold. Transfection of higher amounts of EYFP-PPAR{alpha} encoding vector did not increase transcriptional activity significantly, suggesting that at 50 ng a plateau had almost been reached (Fig. 1C, inset). Similar activation profiles were obtained for wild-type and EYFP fusions to PPAR{beta} and PPAR{gamma}1 (data not shown). These experiments show that the chimeras are active but induce transcription to reduced levels. Interestingly, the loss of activity caused by the EYFP tag was comparable in the N- and C-terminal chimeras. Decreased ligand affinity did not account for this impairment, since increasing the concentration of ligand up to 40 times did not further enhance transactivation, and both wild type and chimeric receptors reached a plateau at the same ligand concentrations (Fig. 1D). Moreover, ligand-dependent recruitment of p300 was not altered by the presence of the EYFP moiety in the pull-down assay (Fig. 1B). Altogether, these results demonstrate that the chimeric proteins are functional but display reduced transcriptional activities that do not result from a major defect in DNA binding (meaning that heterodimerization with RXR is not altered either), ligand binding, or recruitment of p300. These proteins can thus be used for further functional analysis.

EYFP-PPARs Are Localized in the Nucleus and Exhibit Three Distinct Expression Patterns—Insuring that expression levels of EYFP-PPARs are close to those of the endogenous proteins is a requisite for the biological relevance of the observations. We thus compared by Western blot the expression levels of EYFP-PPAR{alpha} in transfected COS-7 cells to those of the wild-type receptor in mouse liver and kidney (Fig. 1E). Rather than using a housekeeping gene whose relative expression level in COS-7, liver, and kidney cells is not known, we adjusted total protein concentration in the lysates for the comparison of the different samples. Transfections with 200 ng of vector per cm2 plate and an efficiency of 60–70% give average expression levels that are in the physiological range. These conditions were therefore used for the initial localization studies.



View larger version (47K):
[in this window]
[in a new window]
  		FIG. 1.
Functional characterization of the EYFP-PPARs. A, Western blot analysis of EYFP-PPAR{alpha}, EYFP-PPAR{beta}, and EYFP-PPAR{gamma} expression in transfected COS-7 cells. Samples were resolved as described under "Experimental Procedures" with isotype-specific antibodies. B, independent DNA and cofactor interaction assays were performed using either a biotinylated double-stranded oligonucleotide containing a PPRE (DNA pull-down) or GST-p300 (cofactor pull-down). Interactions with PPAR{alpha}, EYFP-PPAR{alpha}, or PPAR{alpha}-EYFP from COS-7 cell extracts were analyzed in the absence or presence of 100 µM of Wy14,643 and resolved with an anti-PPAR{alpha} antibody. C, COS-7 cells were transfected with a (PPRE)3-Luc reporter construct, increasing amounts of expression vectors for PPAR{alpha}, EYFP-PPAR{alpha}, or PPAR{alpha}-EYFP, and a control expression vector for Renilla luciferase. They were then grown 18 h in the presence or absence of 10–5 M Wy14,643. Each point was performed in triplicate, and firefly luciferase values were normalized to Renilla luciferase activity. D, transfections were performed as in described for C with 500, 50, and 50 ng of vectors for PPAR{alpha}, PPAR{alpha}-EYFP, or EYFP-PPAR{alpha}, respectively, and relative luciferase activity was analyzed after treatment with increasing concentrations of Wy14,643. E, Western blot analysis of PPAR{alpha} expression levels in protein extracts from tissues and COS-7 cells transfected with increasing amounts of an expression vector for EYFP-PPAR{alpha} (0, 10, 50, 100, and 200 ng/cm2). Identical extraction protocols were used, and equal amounts of total protein extracts were loaded on the gel. WT, wild type.

 
COS-7 cells were transfected with expression vectors for EYFP-PPARs and observed by confocal imaging. EYFP-PPAR{alpha} was exclusively localized in the nucleus, both in the presence and absence of ligand, and was always excluded from nucleoli. Three different subnuclear localization patterns were observed (Fig. 2A). Some cells exhibited a diffuse labeling of the nucleoplasm, whereas others displayed patterns that we named flakes and foci. The same nuclear patterns were observed with the other PPAR isotypes or RXR{alpha} (data not shown). The percentage of each pattern remained unaffected by treatment with specific PPAR ligands (Fig. 2C and data not shown). As a control, a similar experiment was conducted with ER{alpha}, which was shown to form speckles in the nuclei of cells treated with estradiol (16, 17). Indeed, in MCF-7 cells (Fig. 2, D and E) as well as in COS-7 cells (data not shown) EYFP-ER{alpha} exhibited a diffuse pattern that was reshaped upon ligand treatment to a speckled pattern in all cells analyzed. Moreover, although the resolution of light imaging does not allow a precise description of the individual shape of flakes and speckles, a careful examination of the overall aspect of the nuclei allows to distinguish the two patterns. The speckles look like fuzzy patches fading in a diffuse background, whereas the structures formed by PPARs look sharper and more contrasted. These results suggest that the structures displayed by PPAR and ER reflect different nuclear organizations.

As a first approach to understand the significance of the three patterns obtained for EYFP-PPARs, we measured the mean fluorescence intensity as a readout of the expression level within the cell under examination (Fig. 2B). Data were extracted from images acquired with identical microscope settings (same laser power and detector gain). The three patterns were characterized by intensity profiles differing on the maximum as well as on the variance of the fluorescence signal (see profiles along white lines in Fig. 2A). Cells with flakes and foci exhibited a fluorescent signal in average five times higher than cells with a diffuse pattern. Similar results were obtained when PPAR{alpha} was fused to the N or C terminus of EYFP. Thus, whereas Western blot analysis showed that the average expression level of EYFP-PPAR{alpha} in transfected cells was in the physiological range, microscopy analysis revealed important intercellular differences in expression levels. In particular, cells displaying flakes and foci were brighter than cells displaying a diffuse pattern, suggesting that the flakes and foci observed may result from overexpression of EYFP-PPAR{alpha} in the cell analyzed. To test this hypothesis, we analyzed cells transfected with decreasing amounts of expression vector. As shown in Fig. 2F, the percentage of cells displaying flakes and foci decreased in a dose-dependent manner when lower amounts of vector were used.



View larger version (52K):
[in this window]
[in a new window]
  		FIG. 2.
Expression of EYFP-PPAR{alpha} in cells results in three different ligand-independent subnuclear localization patterns. COS-7 (A–C) or MCF-7 (D and E) cells were transfected with 200 ng/cm2 of expression vectors for EYFP-PPAR{alpha} (A–C) or EYFP-ER{alpha} (D and E) and analyzed on a Leica TCS SP2 AOBS confocal microscope. A, three typical localization patterns were observed in living cells expressing EYFP-PPAR{alpha}. Fluorescence intensity fluctuation along the white line is presented under each picture. While quantification of fluorescence intensities along the white line was done on pictures acquired with identical settings (same laser power and detector gain), images with similar intensities were obtained by adjusting laser power and photomultiplier gain for each cell. Since maximal intensity values varied greatly between cell types (from 1 to 34), the fluorescence profiles had to be rescaled for presentation. B, different localization patterns are associated with different expression levels of EYFP-PPAR{alpha}. Quantification of fluorescence intensities was done on pictures acquired with identical settings. C, the proportion of each localization pattern is not influenced by 10 µM Wy14,643. D, the continuous perfusion of 10 nM 17{beta}-estradiol induces the formation of speckles whose aspect differs from the flakes and foci observed with PPAR. E, ER forms speckles in a ligand-dependent manner in all transfected cells. F, transfecting decreasing amounts of EYFP-PPAR{alpha} expression vector decreases the proportion of cells exhibiting flakes and foci. All quantitative analyses were performed on at least 100 nuclei.

 
The use of a fluorescent chimeric protein may introduce a bias by potentially preventing the interaction of PPAR with partners dictating its localization within the cell. To confirm our results, immunolabeling experiments of the endogenous alpha and beta isotypes were performed on sections from various PPAR-expressing tissues. To assess the specificity of the labeling, we checked that (i) absence of the primary antibody, (ii) incubation of the primary antibody with the epitope peptide, and (iii) labeling of sections from PPAR knock-out mice resulted in no or very faint background labeling. Only an antibody directed against PPAR{beta} fully fulfilled these requirements. In line with our live cell data, we observed a diffuse nuclear localization of PPAR{beta} in wounded skin sections (Fig. 3), a condition under which the expression of PPAR{beta} is activated in keratinocytes (36). The absence of flakes or foci in vivo raised the question of the relevance of these substructures in transfected cells. Indeed, speckle formation is an important feature of the behavior of certain nuclear receptors, and to avoid misinterpretation, it is of importance to clarify the physiological relevance of speckle-like patterns such as flakes and foci.

One possibility was that these structures result from the aggregation of the EYFP fusion proteins. Such aggregates should favor the formation of PPAR homodimers that could be detected by FRET. Cyan and yellow fluorescent proteins (ECFP and EYFP) were used as donor and acceptor fluorophores. As controls for the absence and presence of FRET we used cells either co-transfected with separate expression vectors for EYFP and ECFP or with an expression vector encoding EYFP and ECFP in a single protein. Energy transfer occurred between PPAR{alpha}-ECFP and PPAR{alpha}-EYFP in cells with flakes and foci patterns and was significantly higher than in the negative control where ECFP and EYFP were co-expressed alone (Fig. 4A). The FRET obtained did not result from the weak dimerization of ECFP and EYFP (41), since FRET was neither detected in control cells expressing ECFP and EYFP alone nor in cells expressing PPARs tagged at their N terminus. To evaluate FRET in cells with a diffuse pattern, microscope settings required to be adjusted to the lower level of fluorescence (higher laser power and detector gain). In these cells, the normalized FRET signal between PPAR{alpha}-ECFP and PPAR{alpha}-EYFP was not statistically different from the negative control (Fig. 4B). These results therefore reveal that PPAR{alpha} aggregates only in cells exhibiting flakes and foci patterns. Co-expressing unlabeled RXR{alpha} affected neither flakes and foci formation nor FRET (data not shown). Since PPARs only activate transcription as heterodimers with RXR, these results support the idea that these structures correspond to a transcriptionally inactive pool of receptor, resulting from its overexpression.



View larger version (93K):
[in this window]
[in a new window]
  		FIG. 3.
PPAR{beta} displays a diffuse expression in the nucleus of keratinocytes in wounded skin sections. Wounded skin sections were immunolabeled for PPAR{beta} using a fluorescein isothiocyanate-coupled secondary antibody as described under the methods section. Two magnifications are shown. SC, stratum corneum; HF, hair follicle.

 



View larger version (60K):
[in this window]
[in a new window]
  		FIG. 4.
FRET and FRAP analysis of the three EYFP-PPAR expression patterns. A and B, live COS-7 cells transfected with PPAR{alpha}-EYFP, and PPAR{alpha}-ECFP expression vectors were subjected to FRET analysis. A, NFRET in the nuclei of cells displaying flakes and foci compared with NFRET in cells expressing free or linked EYFP and ECFP. Each point corresponds to the average of at least 30 cells. B, same as A but in cells with a diffuse pattern. Note that A and B are independent measurements using different settings adapted to expression levels. *, statistically significant difference with the negative control (ECFP + EYFP) according to a t test with p value < 0.01. C, live COS-7 cells expressing EYFP-PPAR{alpha} and treated with 10 µM Wy14,643 were subjected to FRAP analysis on a Leica TCS SP2 AOBS microscope. For the diffuse pattern, the loss of intensity over the entire nucleus reflects the bleaching of an important proportion of molecules, due to the diffusion of these molecules through the illuminated area during bleaching. Fluorescence recoveries corrected for the bleaching of the entire nucleus as a function of time are plotted in the right panels. Note that despite the high differences in EYFP-PPAR expression levels, fluorescence intensity looks similar for each cell type due to the adjustment of laser power and photomultiplier gain.

 
The mobility of nuclear proteins is an important parameter to understand the temporal organization of nuclear processes and their adaptation to physiological challenges. Thus, we first investigated by FRAP the mobility of PPARs in cells exhibiting different fluorescence profiles. In cells with a diffuse pattern, EYFP-PPAR{alpha} (Fig. 4C) as well as EYFP-PPAR{beta} and EYFP-PPAR{gamma} (data not shown) were highly mobile, and no immobilization of the proteins was observed as total re-colonization of the bleached zone could be obtained. When cells displaying flakes or foci patterns were photobleached, only 40% of the initial fluorescence signal could be recovered, both in the presence and absence of ligand, therefore revealing a high degree of immobilization of the receptor in those structures (Fig. 4C). It is noteworthy that cells in which a heterogeneous labeling is hardly distinguishable from the diffuse background already display altered dynamics (Fig. 4C). Not only the degree but also the rate of recovery was extremely low, indicating that very limited shuttling occurs between foci. Together with the previous demonstration by FRET of aggregate formation, the FRAP data further indicate that flakes and foci constitute an inactive cellular pool.

These results demonstrating the nonphysiological formation of flakes and foci suggested that the aggregated receptors might undergo an active degradation process. Cells expressing EYFP-PPAR{alpha} were therefore immunolabeled with antibodies directed against the 20 S subunits of the proteasome or against ubiquitylated proteins. A clear co-localization between the 20 S proteasome and the flakes and foci could be observed (Fig. 5A), whereas the patterns observed with the antibody directed against ubiquitylated proteins did not overlap with these structures (Fig. 5B).

FRAP and FCS Study of PPAR Mobility in Diffuse Cells— The effect of ligand treatment on PPAR mobility was then investigated for the three PPAR isotypes as well as for RXR in the relevant model of a diffuse expression pattern (Fig. 6). As outlined previously, the diffusion of EYFP-PPARs was very fast and no immobilization of the receptors was observed. Ligand treatment did not influence the recovery rates (Fig. 6, A, C, and D) and the half recovery times of both liganded and unliganded receptors were estimated in the 100-millisecond time range (Table I). As PPARs are active as heterodimers with RXR, we analyzed the influence of RXR on PPAR mobility. Co-expressing unlabeled RXR{alpha} did not affect the recovery of EYFP-PPAR{alpha} both in the absence and presence of a PPAR{alpha} ligand (Fig. 6E). Moreover, EYFP-RXR{alpha} displayed a diffusion similar to PPARs in the absence of ligand (Fig. 6E and Table I). As a control of ligand effect on mobility, the diffusion of EYFP-ER{alpha} was analyzed in the absence and presence of 17{beta}-estradiol both in COS-7 (Fig. 6B) and MCF-7 cells (data not shown). In the absence of ligand, 10% of the receptors were immobilized whereas estrogen treatment induced an immobilization of 32% of the receptors and a 3.3-fold increase of the half-recovery time (Table I), in agreement with previous reports (18, 19, 27).



View larger version (50K):
[in this window]
[in a new window]
  		FIG. 5.
EYFP-PPAR flakes and foci are enriched in 20 S proteasome but not in ubiquitylated proteins. COS-7 cells transfected with EYFP-PPAR{alpha} were fixed and immunolabeled with an antibody directed against all the {alpha} and {beta} subunits of the 20 S proteasome (A) or against ubiquitylated proteins (B). The secondary antibody was coupled to Alexa594, and nuclei were stained with DAPI. The laser power and detector gain of the EYFP settings were adapted to expression levels in each cell, but the DAPI and Alexa594 settings were kept constant. No signal was detected in the Alexa594 channel when primary antibodies were omitted.

 



View larger version (60K):
[in this window]
[in a new window]
  		FIG. 6.
FRAP reveals that EYFP-PPARs are highly mobile both in ligand treated and untreated cells. Live COS-7 cells displaying a diffuse pattern for EYFP-PPAR{alpha} (A), EYFP-ER{alpha} (B), EYFP-PPAR{beta} (C), EYFP-PPAR{gamma}1 (D), EYFP-PPAR{alpha} with wild-type RXR{alpha} (E) or EYFP-RXR{alpha} (F) were subjected to FRAP analysis on a Zeiss LSM510 microscope in the absence or presence of the respective ligands. For each condition, the normalized fluorescence recovery was averaged over 12 cells.

 


View this table:
[in this window]
[in a new window]
  		TABLE I
Quantification of FRAP recovery curves

Half-recovery times and percentages of immobilization were extracted from the curves presented in Fig. 5 as described under "Experimental Procedures."

 
Altogether, our FRAP studies reveal that PPARs and RXR are highly mobile receptors which are not immobilized upon ligand treatment. This study also highlights that liganded PPARs and ER differ not only in their subnuclear localization but also in their mobility.

Fluorescence correlation spectroscopy is a method based on the analysis of fluctuations of fluorescence intensity due to the diffusion of a labeled protein through a very small volume (in the range of 1 µm3) (42, 43). It allows us to study diffusion of mobile molecules at a higher spatial and temporal (microsecond range) resolution than FRAP.

FCS measurements were done on COS-7 cells expressing EYFP, EYFP-PPAR{alpha}, EYFP-PPAR{beta}, or EYFP-PPAR{gamma}. Although we observed a pronounced heterogeneity of diffusion times for each individual measurement (Fig. 7A), data were fitted with a one-component model of free diffusion (Fig. 7B; Table II) with no necessity to imply a second slower component, a reduced dimensionality factor, or anomalous diffusion (44). The respective concentrations of all the fluorescent proteins were estimated to range between 3 and 100 nM, after initial photobleaching. Assuming that the volume of the cell nucleus is 2000 µm3, the average number of fluorescent molecules varies between 3.600 and 120.000 per nucleus. The average diffusion coefficients (D) were respectively 19.7 ± 7.8 µm2·s–1 for EYFP alone and ranged from 4.8 to 5.5 µm2·s–1 for EYFP-PPARs (Fig. 7, C–E; Table II). Since the D value is inversely related to the size of the diffusing particle, EYFP-PPARs were expected to have smaller diffusion coefficients than EYFP alone. This is indeed the case but the estimated sizes of the EYFP-PPAR complexes are in the range of mega-daltons, assuming their free diffusion. These values suggest that in the absence of ligand, PPARs are associated with high molecular mass complexes and/or transiently interact with relatively immobile components of the nucleus.


View this table:
[in this window]
[in a new window]
  		TABLE II
Diffusion coefficients of EYFP-PPAR complexes

Masses were estimated from the average diffusion coefficients as described under "Experimental Procedures." They are hypothetical and calculated under the assumption that the diffusion time of EYFP and EYFP-PPAR is determined by normal diffusion in a viscous (nuclear) medium.

 
Interestingly, ligand binding reduced significantly the average mobility of EYFP-PPARs to 3.2 ± 2.0 µm2·s–1, 3.5 ± 2.0 µm2·s–1, and 2.3 ± 1.1 µm2·s–1 for the {alpha}, {beta}, and {gamma} isotypes, respectively (Fig. 7, C–E; Table II). This shift in mobility indicates that the conformational change induced by ligand results in the docking of new factors to the receptor and/or strengthens the interaction with slow nuclear components.

PPAR and RXR Form Heterodimers in Living Cells in the Absence of Ligand—Our FCS measurements suggested that PPARs contact numerous nuclear components, as suggested by the broad distribution of the diffusion coefficients, even in the absence of ligand. One question that has never been clearly answered so far is whether PPAR and RXR form heterodimers prior to ligand binding. A first clue was that PPAR and RXR exhibit similar diffusion coefficients (Fig. 7F; Table II), but FRET experiments were necessary to prove a direct interaction in living cells. Cells were transfected with combinations of expression vectors for ECFP/PPAR{alpha}, ECFP/PPAR{beta}, ECFP/PPAR{gamma}, and EYFP/RXR{alpha} giving equivalent expression levels of donor and acceptor proteins (data not shown). Energy transfer between any PPAR-ECFP and RXR{alpha}-EYFP was significantly higher than in the negative control where ECFP and EYFP were co-expressed alone (Fig. 8A). This positive FRET signal yet occurred at lower levels than in the positive control were CFP and YFP are fused, possibly because of less favorable fluorophore positioning in the PPAR-ECFP/RXR{alpha}-EYFP dimer. While adding ligand did not change FRET values for PPAR{beta} and PPAR{gamma}, addition of a PPAR{alpha} ligand induced a small but reproducible increase of FRET. This suggests that ligand binding either increases the affinity of PPAR{alpha} for RXR or orientates the ECFP moiety in a more favorable manner for FRET. Note that FRET did not occur between the N-terminal fusion proteins ECFP-PPARs and EYFP-RXR{alpha}, suggesting that, in such heterodimers, the N-terminal domains of the receptors are too far from each other to allow energy transfer. To localize heterodimer formation within the nucleus, a pixel-by-pixel analysis was performed on cells transfected with PPAR{alpha}-ECFP and RXR{alpha}-EYFP (Fig. 8B). When the FRET channel was corrected for the spectral ECFP and EYFP bleed-throughs and for fluorophore expression levels, a NFRET signal could be observed throughout the entire nucleus, showing that heterodimer formation is not restricted to a subcompartment. Similar distributions were observed in the absence (Fig. 8B) or presence (data not shown) of ligand. Altogether, these FRET experiments strongly suggest that, even in the absence of ligand, PPAR and RXR readily form heterodimers in the nucleus of living cells.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Understanding protein behavior, localization, trafficking, and participation to complexes in living cells has remained so far difficult. With that respect, our analysis provides important clues to establish the appropriate and biologically relevant settings to further study fluorescent fusion proteins in living cells. Moreover, a detailed approach allowed a reliable examination of the behavior of the three PPAR isotypes and thereby unveiled important new insights on PPAR mode of action.

Criteria for a Relevant Model to Study PPAR Action in Living Cells—First, the different properties of the fluorescent receptors were evaluated. Ligand, DNA, and p300 binding were not affected by addition of the EYFP moiety, and the various constructions were able to activate transcription, albeit to a lower extent than their wild-type counterparts. Proper DNA binding also attested of their normal capabilities to heterodimerize with RXR. However, these experiments are not sensitive enough to detect subtle changes and the decreased transcriptional activity of the fusion proteins could result from the addition of small impairments. Also, we cannot rule out that the binding of other cofactors than p300 in the cell is affected, accounting also for the reduced transactivation observed.



View larger version (31K):
[in this window]
[in a new window]
  		FIG. 7.
Ligands reduce the diffusion rates of EYFP-PPARs. Diffusion of EYFP (A and B), EYFP-PPAR{alpha} (C), EYFP-PPAR{beta} (D), EYFP-PPAR{gamma} (E), and EYFP-RXR (F) was analyzed by FCS in transfected COS-7 cells in the absence or presence of the respective ligands. B, the autocorrelation curves, shown here for EYFP, were fitted with a one-component model of free diffusion. A and C–F, frequency histograms of the diffusion coefficients representing at least 200 measurements.

 
The second important issue concerns the localization of PPARs and the discrimination between relevant speckles and nonfunctional aggregates. We observed that the three PPAR isotypes and RXR{alpha} are localized in the nucleus of living COS-7 cells and excluded from nucleoli, in accordance to previous reports (22, 45, 46). Immunolabeling of PPAR{beta} in mouse skin sections corroborated the results obtained with EYFP-PPARs. PPARs did not form the physiological ligand-induced speckles observed for ER. Neither did RXR{alpha}, in contrast to previously reported data (22). The fluorescent patterns observed after transfection, which we deliberately termed flakes and foci and not speckles, appeared to be artifacts due to overexpression and aggregation of the fusion proteins in individual cells. Importantly, we also observed such flakes and foci for RXR{alpha} and ER{alpha} in cells expressing high levels of the receptors. Abnormal localization of the estrogen receptor due to overexpression has been also reported before and was shown to bias studies on nuclear matrix association (16, 47, 48). Problems linked to the overexpression of RXR have also been pointed to recently (49). This immobilization in nonfunctional structures is therefore likely to be of general occurrence for nuclear receptors and possibly for other nuclear proteins upon transfection. Mislocalization and abnormal mobilities of proteins due to overexpression or mutations have been linked to nuclear matrix association and/or proteasome function in several studies (see Ref. 48 for a review). We observed a co-localization between the flakes and foci formed by EYFP-PPAR{alpha} and the subunits of the 20 S proteasome, which constitute the catalytic core of the complex, but these structures were not enriched in ubiquitin. Interestingly, some unfolded proteins can be degraded by the proteasome in the absence of ubiquitylation (50). It is therefore tempting to speculate that the flakes and foci correspond to an accumulation of misfolded receptors that the cell tries to remove using the proteasome pathway.



View larger version (52K):
[in this window]
[in a new window]
  		FIG. 8.
PPARs and RXR{alpha} form heterodimers in living cells in the absence of ligand. Live COS-7 cells transfected with 100 and 50 ng/cm2 PPARs-ECFP and RXR{alpha}-EYFP, respectively, were subjected to FRET analysis. A, NFRET in the nuclei of cells with a diffuse pattern compared with NFRET in cells transfected with expression vectors for free or linked EYFP and ECFP proteins. At least 50 cells were analyzed. * and **, statistically significant difference with the negative control ECFP + EYFP (*) or with the corresponding vehicle treatment (**) according to a t test with p value < 0.01. B, pixel-by-pixel analysis of FRET on a cell expressing PPAR{alpha}-ECFP and RXR{alpha}-EYFP, performed with the PixFRET plug-in for the ImageJ software.

 
Thus, our results point out several technical pitfalls linked to live cell imaging: (i) when assessing the activity of a GFP-tagged transcription factor, it is of importance to compare activity at similar expression levels of the chimera and the wild-type proteins; (ii) it is also important to precisely characterize the nature and the conditions of occurrence of subnuclear structures to rule out potential artifacts. The occurrence of ligand-induced speckles should also be demonstrated by following a single cell before and after ligand addition and by statistically describing the phenomenon reported at the cell population level; (iii) since over the whole population important differences in the level of expression of transfected proteins are observed, assessing mean expression levels by Western blot is not sufficient to define relevant experimental conditions, hence, appropriate selection of the individual cells analyzed is necessary; (iv) when possible, immunolabeling of the endogenous protein, like it was done here on skin sections, should be performed to support live cell studies.

PPARs Are Associated with RXR Prior to Ligand Binding— Our FRET data demonstrate for the first time that in living cells PPARs readily associate with RXR in the absence of ligand. This result challenges the current general view of PPAR action where heterodimerization with RXR is often presented as a consequence of ligand binding. Moreover, our data also suggest that PPAR/RXR dimerization occurs prior to promoter binding because: (i) the receptors are in large excess with respect to the number of PPAR target genes, (ii) the FRET signal is present all over the nucleus with no particular sign of enrichment in any region, and (iii) we recently published chromatin immunoprecipitation experiments showing that stable promoter binding occurs in vivo only after ligand treatment on the PDK1 promoter (35).

PPARs Have Unexpected Small Diffusion Coefficients in Living Cells—When studied by FRAP, PPARs appear as highly mobile nuclear receptors which are not immobilized upon ligand binding, as similarly reported for RAR and TR (19, 51) and in contrast to ER and GR (18, 19, 27, 28). These results therefore suggest that ligand-induced immobilization of nuclear receptors could be a hallmark of homodimerization. However, the limited temporal resolution of this technique does not allow to observe very fast events such as transient interactions for example.

FCS, a technique providing quantitative information on diffusion of fluorescent molecules in the microsecond time range, was used here for the first time to assess the mobility of a nuclear receptor in living cells. A very interesting result is that unliganded PPARs have diffusion coefficients (~5 µm2·s–1), which are much smaller than those expected if the receptors were freely diffusing in the nucleus as monomers (~14 µm2·s–1) or even as heterodimers with RXR (~11.5 µm2·s–1). These data actually reflect the association of PPARs with other proteins and/or their transient interactions with very slow nuclear components. Assuming that PPARs are associated with soluble factors only, a diffusion coefficient of 5 µm2·s–1 indicates the engagement in a complex of 1 to 2 MDa (Table II). Such factors may be corepressors (52, 53) or alternatively chaperones that are thought to be essential at least for the diffusion properties of GR and PR (30). However, it is highly probable that PPARs also interact transiently with rather immobile components such as the nuclear matrix or chromatin, as suggested recently for other nuclear factors (54, 55).

Interestingly, the mobility of the three PPAR isotypes was reduced upon ligand binding. This may reflect the recruitment of cofactors, leading to the formation of complexes of higher molecular masses. However, the estimated sizes of these complexes are very important (Table II) and it is likely that the decrease in diffusion coefficients due to ligand binding also reflects enhanced interactions with very slow nuclear components such as chromatin. These increased interactions could potentially result from either an increase in affinity or from a stabilization of the interactions leading to longer binding events. Since the number of PPAR target genes in a cell is low (probably tens to hundreds) compared with the number of EYFP-PPAR molecules, some of the reported effects may result from interactions with bona fide PPREs, but most of them probably result from transient and unspecific interactions at sites resembling PPREs but not located within active promoters, as described previously for NF-{kappa}B (51). Interestingly, a recent publication proposes a model where transcription factors permanently perform a three-dimensional scanning of the genome (55). Extrapolating this model to PPARs is a possibility we are currently assessing, among others, by studying the mobility of PPAR mutants deficient for DNA binding and cofactor recruitment.

Altogether, this study demonstrates that both in the presence and absence of ligand, all PPARs are engaged in complexes of very high molecular masses and/or in transient interactions with very slow nuclear components. Moreover, PPAR and RXR are readily associated in the cell prior to ligand binding. Importantly, we also demonstrate here the usefulness of FCS when studying the mobility of nuclear receptors in living cells.


   FOOTNOTES
 
* This work was supported by grants from the Université Lausanne/Ecole Polytechnique Fédérale Lausanne fund, the National Research Project 50, the Swiss National Science Foundation, and the Etat de Vaud (to W. W. and B. D.) and by the Research Council (to C. T.) and the grant GOA 2001/2 (to Y. E.) of the Katholieke Universiteit Leuven. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{diamondsuit} This article was selected as a Paper of the Week. Back

§ These authors contributed equally to this work. Back

|| To whom correspondence should be addressed: Center for Integrative Genomics, Université de Lausanne, Baatiment de Biologie, CH-1015 Lausanne, Switzerland. Tel.: 41-21-692-41-40; Fax: 41-21-692-41-15; E-mail: beatrice.desvergne{at}unil.ch.

1 The abbreviations used are: TR, thyroid hormone receptor; VDR, vitamin D receptor; RAR, retinoic acid receptor; PPAR, peroxisome proliferator-activated receptor; PPRE, PPAR response element; RXR, retinoid X receptor; FP, fluorescent protein; GFP, green FP; YFP, yellow FP; CFP, cyan FP; EYFP, enhanced YFP; ECFP, enhanced CFP; FRAP, fluorescence recovery after photobleaching; FCS, fluorescence correlation spectroscopy; FRET, fluorescence resonance energy transfer; GR, glucocorticoid receptor; AR, androgen receptor; PR, progesterone receptor; MR, mineralocorticoid receptor; PBS, phosphate-buffered saline; BSA, bovine serum albumin; DAPI, 4',6-diamidino-2-phenylindole; RXR, retinoid X receptor. Back


   ACKNOWLEDGMENTS
 
We thank the members of the microscopy platform of the NCCR "Frontiers in Genetics" program; Drs. H. Vogel, M. Prümmer, and H. Jankevics for access and training on the LSM510 microscope and for helpful discussions; and Drs. R. M. Evans and J. M. Tavaré for the gifts of the (PPRE)3-luciferase and the ECFP-DEVD-EYFP constructs. Chuan Young Ng is acknowledged for technical help with immunohistochemistry.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Misteli, T. (2001) Science 291, 843–847[Abstract/Free Full Text]
  2. Lamond, A. I., and Spector, D. L. (2003) Nat. Rev. Mol. Cell. Biol. 4, 605–612[CrossRef][Medline] [Order article via Infotrieve]
  3. Pederson, T. (2001) Cell 104, 635–638[CrossRef][Medline] [Order article via Infotrieve]
  4. Robyr, D., Wolffe, A. P., and Wahli, W. (2000) Mol. Endocrinol. 14, 329–347[Free Full Text]
  5. Nuclear Receptors Nomenclature Committee (1999) Cell 97, 161–163[CrossRef][Medline] [Order article via Infotrieve]
  6. Michalik, L., Desvergne, B., and Wahli, W. (2004) Nat. Rev. Cancer 4, 61–70[CrossRef][Medline] [Order article via Infotrieve]
  7. Escher, P., and Wahli, W. (2000) Mutat. Res. 448, 121–138[Medline] [Order article via Infotrieve]
  8. Hihi, A. K., Michalik, L., and Wahli, W. (2002) Cell Mol. Life Sci. 59, 790–798[CrossRef][Medline] [Order article via Infotrieve]
  9. Lippincott-Schwartz, J., and Patterson, G. H. (2003) Science 300, 87–91[Abstract/Free Full Text]
  10. Htun, H., Barsony, J., Renyi, I., Gould, D. L., and Hager, G. L. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4845–4850[Abstract/Free Full Text]
  11. Tyagi, R. K., Lavrovsky, Y., Ahn, S. C., Song, C. S., Chatterjee, B., and Roy, A. K. (2000) Mol. Endocrinol. 14, 1162–1174[Abstract/Free Full Text]
  12. Tomura, A., Goto, K., Morinaga, H., Nomura, M., Okabe, T., Yanase, T., Takayanagi, R., and Nawata, H. (2001) J. Biol. Chem. 276, 28395–28401[Abstract/Free Full Text]
  13. Lim, C. S., Baumann, C. T., Htun, H., Xian, W., Irie, M., Smith, C. L., and Hager, G. L. (1999) Mol. Endocrinol. 13, 366–375[Abstract/Free Full Text]
  14. Fejes-Toth, G., Pearce, D., and Naray-Fejes-Toth, A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2973–2978[Abstract/Free Full Text]
  15. Racz, A., and Barsony, J. (1999) J. Biol. Chem. 274, 19352–19360[Abstract/Free Full Text]
  16. Stenoien, D. L., Mancini, M. G., Patel, K., Allegretto, E. A., Smith, C. L., and Mancini, M. A. (2000) Mol. Endocrinol. 14, 518–534[Abstract/Free Full Text]
  17. Htun, H., Holth, L. T., Walker, D., Davie, J. R., and Hager, G. L. (1999) Mol. Biol. Cell 10, 471–486[Abstract/Free Full Text]
  18. Reid, G., Hubner, M. R., Metivier, R., Brand, H., Denger, S., Manu, D., Beaudouin, J., Ellenberg, J., and Gannon, F. (2003) Mol. Cell 11, 695–707[CrossRef][Medline] [Order article via Infotrieve]
  19. Maruvada, P., Baumann, C. T., Hager, G. L., and Yen, P. M. (2003) J. Biol. Chem. 278, 12425–12432[Abstract/Free Full Text]
  20. Baumann, C. T., Maruvada, P., Hager, G. L., and Yen, P. M. (2001) J. Biol. Chem. 276, 11237–11245[Abstract/Free Full Text]
  21. Bunn, C. F., Neidig, J. A., Freidinger, K. E., Stankiewicz, T. A., Weaver, B. S., McGrew, J., and Allison, L. A. (2001) Mol. Endocrinol. 15, 512–533[Abstract/Free Full Text]
  22. Prufer, K., Racz, A., Lin, G. C., and Barsony, J. (2000) J. Biol. Chem. 275, 41114–41123[Abstract/Free Full Text]
  23. DeFranco, D. B. (2002) Mol. Endocrinol. 16, 1449–1455[Abstract/Free Full Text]
  24. Grande, M. A., van der Kraan, I., de Jong, L., and van Driel, R. (1997) J. Cell Sci. 110, 1781–1791[Abstract]
  25. McNally, J. G., Muller, W. G., Walker, D., Wolford, R., and Hager, G. L. (2000) Science 287, 1262–1265[Abstract/Free Full Text]
  26. Hinojos, C. A., Sharp, Z. D., and Mancini, M. A. (2005) Trends Endocrinol. Metab. 16, 12–18[CrossRef][Medline] [Order article via Infotrieve]
  27. Stenoien, D. L., Patel, K., Mancini, M. G., Dutertre, M., Smith, C. L., O'Malley, B. W., and Mancini, M. A. (2001) Nat. Cell Biol. 3, 15–23[CrossRef][Medline] [Order article via Infotrieve]
  28. Schaaf, M. J., and Cidlowski, J. A. (2003) Mol. Cell. Biol. 23, 1922–1934[Abstract/Free Full Text]
  29. Stavreva, D. A., Muller, W. G., Hager, G. L., Smith, C. L., and McNally, J. G. (2004) Mol. Cell. Biol. 24, 2682–2697[Abstract/Free Full Text]
  30. Elbi, C., Walker, D. A., Romero, G., Sullivan, W. P., Toft, D. O., Hager, G. L., and DeFranco, D. B. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 2876–2881[Abstract/Free Full Text]
  31. Llopis, J., Westin, S., Ricote, M., Wang, Z., Cho, C. Y., Kurokawa, R., Mullen, T. M., Rose, D. W., Rosenfeld, M. G., Tsien, R. Y., Glass, C. K., and Wang, J. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 4363–4368[Abstract/Free Full Text]
  32. Bai, Y., and Giguère, V. (2003) Mol. Endocrinol. 17, 589–599[Abstract/Free Full Text]
  33. Lemberger, T., Saladin, R., Vazquez, M., Assimacopoulos, F., Staels, B., Desvergne, B., Wahli, W., and Auwerx, J. (1996) J. Biol. Chem. 271, 1764–1769[Abstract/Free Full Text]
  34. Gelman, L., Zhou, G., Fajas, L., Raspe, E., Fruchart, J. C., and Auwerx, J. (1999) J. Biol. Chem. 274, 7681–7688[Abstract/Free Full Text]
  35. IJpenberg, A., Tan, N. S., Gelman, L., Kersten, S., Seydoux, J., Xu, J., Metzger, D., Canaple, L., Chambon, P., Wahli, W., and Desvergne, B. (2004) EMBO J. 23, 2083–2091[CrossRef][Medline] [Order article via Infotrieve]
  36. Michalik, L., Desvergne, B., Tan, N. S., Basu-Modak, S., Escher, P., Rieusset, J., Peters, J. M., Kaya, G., Gonzalez, F. J., Zakany, J., Metzger, D., Chambon, P., Duboule, D., and Wahli, W. (2001) J. Cell Biol. 154, 799–814[Abstract/Free Full Text]
  37. Xia, Z., and Liu, Y. (2001) Biophys. J. 81, 2395–2402[Medline] [Order article via Infotrieve]
  38. Phair, R. D., and Misteli, T. (2000) Nature 404, 604–609[CrossRef][Medline] [Order article via Infotrieve]
  39. Krouglova, T., Vercammen, J., and Engelborghs, Y. (2004) Biophys. J. 87, 2635–2646[CrossRef][Medline] [Order article via Infotrieve]
  40. Seksek, O., Biwersi, J., and Verkman, A. S. (1997) J. Cell Biol. 138, 131–142[Abstract/Free Full Text]
  41. Zacharias, D. A., Violin, J. D., Newton, A. C., and Tsien, R. Y. (2002) Science 296, 913–916[Abstract/Free Full Text]
  42. Brock, R., Hink, M. A., and Jovin, T. M. (1998) Biophys. J. 75, 2547–2557[Medline] [Order article via Infotrieve]
  43. Dittrich, P., Malvezzi-Campeggi, F., Jahnz, M., and Schwille, P. (2001) Biol. Chem. 382, 491–494[CrossRef][Medline] [Order article via Infotrieve]
  44. Wachsmuth, M., Waldeck, W., and Langowski, J. (2000) J. Mol. Biol. 298, 677–689[CrossRef][Medline] [Order article via Infotrieve]
  45. Patel, H., Truant, R., Rachubinski, R. A., and Capone, J. P. (2005) J. Cell Sci. 118, 175–186[Abstract/Free Full Text]
  46. Akiyama, T. E., Baumann, C. T., Sakai, S., Hager, G. L., and Gonzalez, F. J. (2002) Mol. Endocrinol. 16, 707–721[Abstract/Free Full Text]
  47. Stenoien, D. L., Mielke, M., and Mancini, M. A. (2002) Nat. Cell Biol. 4, 806–810[CrossRef][Medline] [Order article via Infotrieve]
  48. Stenoien, D. L., Simeoni, S., Sharp, Z. D., and Mancini, M. A. (2000) J. Cell. Biochem. Suppl. 35, 99–106[Medline] [Order article via Infotrieve]
  49. Dong, S., Stenoien, D. L., Qiu, J., Mancini, M. A., and Tweardy, D. J. (2004) Mol. Cell. Biol. 24, 4465–4475[Abstract/Free Full Text]
  50. Sheaff, R. J., Singer, J. D., Swanger, J., Smitherman, M., Roberts, J. M., and Clurman, B. E. (2000) Mol. Cell 5, 403–410[CrossRef][Medline] [Order article via Infotrieve]
  51. Martone, R., Euskirchen, G., Bertone, P., Hartman, S., Royce, T. E., Luscombe, N. M., Rinn, J. L., Nelson, F. K., Miller, P., Gerstein, M., Weissman, S., and Snyder, M. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 12247–12252[Abstract/Free Full Text]
  52. Dowell, P., Ishmael, J. E., Avram, D., Peterson, V. J., Nevrivy, D. J., and Leid, M. (1999) J. Biol. Chem. 274, 15901–15907[Abstract/Free Full Text]
  53. Shi, Y., Hon, M., and Evans, R. M. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 2613–2618[Abstract/Free Full Text]
  54. Oesterreich, S., Zhang, Q., Hopp, T., Fuqua, S. A., Michaelis, M., Zhao, H. H., Davie, J. R., Osborne, C. K., and Lee, A. V. (2000) Mol. Endocrinol. 14, 369–381[Abstract/Free Full Text]
  55. Phair, R. D., Scaffidi, P., Elbi, C., Vecerova, J., Dey, A., Ozato, K., Brown, D. T., Hager, G., Bustin, M., and Misteli, T. (2004) Mol. Cell. Biol. 24, 6393–6402[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Reproductive SciencesHome page
G. Chaudhuri
Nuclear Receptors and Female Reproduction: A Tale of 3 Scientists, Jensen, Gustafsson, and O'Malley
Reproductive Sciences, February 1, 2008; 15(2): 110 - 120.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
J. N. Feige, L. Gelman, D. Rossi, V. Zoete, R. Metivier, C. Tudor, S. I. Anghel, A. Grosdidier, C. Lathion, Y. Engelborghs, et al.
The Endocrine Disruptor Monoethyl-hexyl-phthalate Is a Selective Peroxisome Proliferator-activated Receptor {gamma} Modulator That Promotes Adipogenesis
J. Biol. Chem., June 29, 2007; 282(26): 19152 - 19166.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
A. von Knethen, M. Soller, N. Tzieply, A. Weigert, A. M. Johann, C. Jennewein, R. Kohl, and B. Brune
PPAR{gamma}1 attenuates cytosol to membrane translocation of PKC{alpha} to desensitize monocytes/macrophages
J. Cell Biol., February 26, 2007; 176(5): 681 - 694.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Tudor, J. N. Feige, H. Pingali, V. B. Lohray, W. Wahli, B. Desvergne, Y. Engelborghs, and L. Gelman
Association with Coregulators Is the Major Determinant Governing Peroxisome Proliferator-activated Receptor Mobility in Living Cells
J. Biol. Chem., February 16, 2007; 282(7): 4417 - 4426.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
L. Michalik, J. Auwerx, J. P. Berger, V. K. Chatterjee, C. K. Glass, F. J. Gonzalez, P. A. Grimaldi, T. Kadowaki, M. A. Lazar, S. O'Rahilly, et al.
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Pharmacol. Rev., December 1, 2006; 58(4): 726 - 741.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
G.-H. Liu, J. Qu, and X. Shen
Thioredoxin-mediated Negative Autoregulation of Peroxisome Proliferator-activated Receptor {alpha} Transcriptional Activity
Mol. Biol. Cell, April 1, 2006; 17(4): 1822 - 1833.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
D. P. Hewitt, P. J. Mark, and B. J. Waddell
Placental Expression of Peroxisome Proliferator-Activated Receptors in Rat Pregnancy and the Effect of Increased Glucocorticoid Exposure
Biol Reprod, January 1, 2006; 74(1): 23 - 28.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
L. Michalik, J. N. Feige, L. Gelman, T. Pedrazzini, H. Keller, B. Desvergne, and W. Wahli
Selective Expression of a Dominant-Negative Form of Peroxisome Proliferator-Activated Receptor in Keratinocytes Leads to Impaired Epidermal Healing
Mol. Endocrinol., September 1, 2005; 19(9): 2335 - 2348.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/18/17880    most recent
M500786200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feige, J. N.
Right arrow Articles by Desvergne, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feige, J. N.
Right arrow Articles by Desvergne, B.
Related Collections
Right arrow Papers Of The Week
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement